This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
by Zacks Equity Research
Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
Should Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for EQWL
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
by Zacks Equity Research
Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.87, denoting a -1.53% change from the preceding trading day.
GILD Stock Down on Report of Cut in HIV Prevention Spending
by Zacks Equity Research
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash funding for HIV prevention in the country.
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
by Zacks Equity Research
SRPT and INCY are in the spotlight this week following a report of an adverse event and study data, respectively.
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
by Zacks Equity Research
Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.
Novartis Reports Updated Positive Data From Phase III SMA Program
by Zacks Equity Research
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Company News for Mar 20, 2025
by Zacks Equity Research
Companies In The Article Are:TSLA, GIS, GILD, HQY
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
by Zacks Equity Research
Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
by Zacks Equity Research
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
Buy 3 U.S. Giants Flying High Year to Date Defying Severe Volatility
by Nalak Das
Three U.S. bigwigs flying high year to date with more upside are GILD, GE and PGR.
INCY Stock Down on Disappointing Skin Disease Study Data
by Zacks Equity Research
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
Is Invesco S&P 500 Equal Weight ETF (RSP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSP
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
by Ekta Bagri
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the stock to investors.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
by Zacks Equity Research
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GILD vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. VRTX: Which Stock Is the Better Value Option?